a979d6c3-5517-42d5-97ef-9c74f894c255.jpeg

+2 more

Explain why is the drug contraindicated,and explain the adrs and the interactions

Reading File

Finding Sources

Reading File

Finding Sources

Reading File

Finding Sources

I now have sufficient information to provide a thorough explanation. Here is the complete breakdown:

Amlodipine - Contraindications, ADRs & Drug Interactions Explained

Why Is Amlodipine Contraindicated in Those Conditions?

Amlodipine is a dihydropyridine calcium channel blocker (DHP-CCB). Its mechanism - blocking L-type Ca²+ channels - causes smooth muscle relaxation and vasodilation, which reduces systemic vascular resistance and blood pressure. This same mechanism explains every contraindication:

1. Severe Hypotension

Amlodipine is a potent vasodilator. It lowers blood pressure by reducing peripheral vascular resistance. In a patient who already has severely low blood pressure, giving amlodipine will drop BP further, potentially causing circulatory collapse, organ hypoperfusion, and death. There is no safety margin - the drug will worsen what is already a hemodynamic emergency.

2. Cardiogenic Shock

Cardiogenic shock means the heart is failing to pump adequately, causing very low cardiac output and low blood pressure. Amlodipine causes vasodilation and - at high concentrations - can unmask negative inotropic (cardiac-depressant) effects, further reducing the already-failing cardiac output. As confirmed in Goodman & Gilman's Pharmacological Basis of Therapeutics, Ca²+ channel blockers are contraindicated in heart failure with reduced ejection fraction because they can worsen prognosis; in cardiogenic shock this risk is immediate and life-threatening.

3. Left Ventricular Outflow Tract Obstruction (LVOTO)

In conditions like hypertrophic obstructive cardiomyopathy (HOCM), there is dynamic obstruction of blood leaving the left ventricle. Vasodilation from amlodipine drops systemic vascular resistance (afterload), which actually worsens the gradient across the obstruction - blood flows even less effectively out of the LV. Additionally, the reflex tachycardia that amlodipine triggers (due to the blood pressure drop) reduces diastolic filling time, making the obstruction worse. For LVOTO, verapamil (a non-DHP CCB) is actually preferred because its negative chronotropic and inotropic effects are beneficial here. - Harrison's Principles of Internal Medicine 22E, LVOTO section

4. Heart Failure After Acute MI

Following an acute myocardial infarction (MI), the myocardium is stunned and vulnerable. Amlodipine's vasodilatory action triggers reflex sympathetic activation and tachycardia, increasing myocardial oxygen demand at exactly the time the heart cannot meet it. While studies (PRAISE trial) showed amlodipine did not worsen long-term prognosis in stable chronic heart failure (non-ischemic), using it acutely post-MI in the context of heart failure significantly risks hemodynamic deterioration. Goodman & Gilman specifically notes that "immediate-release dihydropyridines in the absence of β-blockers" carry trend toward harm in acute coronary settings.

Adverse Drug Reactions (ADRs) - Explained

Each ADR follows directly from amlodipine's vasodilatory mechanism:

ADR	Mechanism
Peripheral oedema	Vasodilation preferentially dilates arterioles > venules, increasing capillary hydrostatic pressure → fluid leaks into interstitium, especially ankles. Most common ADR of amlodipine.
Hypotension	Direct extension of therapeutic effect - excessive vasodilation drops BP below safe levels.
Palpitations, Tachycardia	Reflex sympathetic activation in response to vasodilation/BP drop → baroreceptors trigger the sympathetic nervous system → increased heart rate.
Bradycardia	Less common with amlodipine than with verapamil/diltiazem, but can occur, especially in overdose or combination with beta-blockers.
Headache, Dizziness, Flushing	Vasodilation of cerebral and cutaneous vessels → headache and flushing; dizziness from relative cerebral hypoperfusion.
Fatigue	Reduced cardiac output at lower blood pressure.
Nausea, Diarrhoea, Abdominal pain	Smooth muscle relaxation extends to the GI tract - reduces motility and alters gastric function.
Tinnitus	Vasodilation affecting inner ear vasculature; inner ear is highly sensitive to perfusion changes.
Muscle cramps, Arthralgia	Ca²+ is required for normal muscle contraction; reduced intracellular Ca²+ entry alters muscle function and may cause cramping.
Thrombocytopenia / Leucopenia	Rare idiosyncratic bone marrow suppression; mechanism not fully established.
Pulmonary oedema, Dyspnoea, Cough	In patients with underlying cardiac dysfunction, vasodilation + fluid redistribution can precipitate pulmonary congestion. Cough is rare (unlike ACE inhibitors); dyspnoea may reflect fluid overload.

Harrison's Principles, Calcium Channel Blockers table; Goodman & Gilman Chapter 31

Drug Interactions - Explained

1. Immunosuppressants (e.g., Cyclosporine, Tacrolimus) → Increased plasma concentration

Amlodipine inhibits CYP3A4 and P-glycoprotein to a mild degree. Cyclosporine and tacrolimus are substrates of CYP3A4 and P-gp. When amlodipine is co-administered, it can slow their metabolism, raising immunosuppressant plasma levels and increasing toxicity risk (nephrotoxicity, neurotoxicity). Your notes correctly state: "↑ systemic plasma concentration." - Comprehensive Clinical Nephrology 7th Ed.

2. Simvastatin → Increased serum concentration of simvastatin

Amlodipine is metabolized by CYP3A4 and also mildly inhibits it. Simvastatin is also primarily metabolized by CYP3A4. When both are taken together, amlodipine inhibits simvastatin's CYP3A4-mediated metabolism, raising simvastatin levels by up to ~77%. This dramatically increases the risk of statin-related myopathy and rhabdomyolysis. This is why guidelines cap simvastatin dose at 20 mg/day when combined with amlodipine. Your notes correctly state: "↑ serum concentration of simvastatin."

3. CYP3A4 Inhibitors → Increased amlodipine plasma concentration

Amlodipine is a substrate of CYP3A4. When CYP3A4 inhibitors (e.g., azole antifungals like ketoconazole/itraconazole, macrolide antibiotics like erythromycin/clarithromycin, HIV protease inhibitors like ritonavir, grapefruit juice) are co-administered, they inhibit the enzyme responsible for breaking down amlodipine. This raises amlodipine blood levels, amplifying its vasodilatory effects and ADR risk (excessive hypotension, oedema). Your notes state "CYP3A4 inhibitors → decrease plasma concentration" - note this appears to be a writing error in your notes; CYP3A4 inhibitors actually increase amlodipine plasma concentration (by blocking its breakdown). CYP3A4 inducers (e.g., rifampicin, phenytoin, carbamazepine) would decrease it.

Quick Summary Table - Interactions

Drug/Class	Effect	Why
Immunosuppressants	↑ immunosuppressant levels	Amlodipine inhibits CYP3A4/P-gp → slows their metabolism
Simvastatin	↑ simvastatin levels → myopathy risk	Both use CYP3A4; amlodipine slows simvastatin clearance
CYP3A4 inhibitors (azoles, macrolides)	↑ amlodipine levels	Inhibit amlodipine's own metabolism → toxicity
CYP3A4 inducers (rifampicin)	↓ amlodipine levels	Speed up amlodipine metabolism → reduced efficacy
Beta-blockers	Additive hypotension + bradycardia	Combined negative cardiovascular effects

Note on your notes: The ADR list in your third image is accurate and complete. The one small error to flag is in the interactions section - CYP3A4 inhibitors increase amlodipine levels (not decrease). Your notes may have meant to write "CYP3A4 inducers → decrease plasma concentration," which would be correct.

62db29c7-5115-4db8-bd04-938fc3f60f5a.jpeg

437565a3-56ea-4500-8506-47c9d9f7d4f2.jpeg

Give me the answer of the appropriate case study

Reading File

Finding Sources

Reading File

Finding Sources

Reading File

Finding Sources

Reading File

Finding Sources

Reading File

I now have comprehensive information. Let me compile the complete case study answer.

Case Study Answer - 65-Year-Old Male with Alcoholic Liver Disease

Understanding the Clinical Picture First

Diagnosis: Decompensated alcoholic liver cirrhosis presenting with:

Ascites (increased abdominal distension)
Hepatic Encephalopathy (HE) (confusion)
Nausea and vomiting
Worsening jaundice

Lab interpretation:

Lab	Patient Value	Normal	Significance
Na+	116 mmol/L	135-145	Severe dilutional hyponatraemia - common in advanced cirrhosis due to ADH activation and water retention
K+	3.8 mmol/L	3.5-5.0	Normal (borderline, monitor closely with diuretics)
Urea	8.5 mmol/L	2.5-7.5	Mildly elevated - may indicate GI bleed or dehydration
Bilirubin	23 g/L	<17 µmol/L	Markedly elevated - severe jaundice from hepatocellular failure
Albumin	23 g/L	35-50 g/L	Severely low - confirms poor synthetic function, contributes to ascites
AST	524 IU/L	<40	Very high - active hepatocellular injury
ALP	18.6 IU/L	44-147	Low-normal ALP in alcoholic liver disease is typical (zinc deficiency)
Prothrombin time	135 sec	11-13 sec	Massively prolonged - severely impaired clotting factor synthesis = high bleeding risk

Question: Discuss the Initial Treatment Plan for Management of Ascites, Nausea, Vomiting & Confusion

1. Management of ASCITES

Pathophysiology recap: In cirrhosis, portal hypertension causes splanchnic vasodilation → activation of RAAS + SNS → aldosterone-driven renal sodium and water retention → ascites formation. This is why aldosterone antagonists are first-line treatment. - Sleisenger & Fordtran's GI and Liver Disease

Step 1 - Sodium Restriction

Restrict dietary sodium to 80-120 mEq/day (approx. 4.6-6.9 g salt/day = "no added salt" diet)
More severe restriction is NOT recommended - poorly tolerated and worsens nutritional status
This patient is already on spironolactone 300 mg QAM, which is appropriate

Step 2 - Review Current Diuretic Therapy

Spironolactone (an aldosterone antagonist) is the first-line diuretic for cirrhotic ascites because hyperaldosteronism is the primary driver of sodium retention
Standard starting dose is 100 mg/day, titrated up to a maximum of 400 mg/day
This patient is on 300 mg - which is within range but at the higher end
However, his Na+ is 116 mmol/L (severe hyponatraemia). This raises concern: spironolactone at high dose can worsen hyponatraemia and AKI. The dose should be reviewed/reduced
If ascites is large-volume (Grade 3), add furosemide at a standard 40 mg alongside spironolactone (ratio 100 mg:40 mg maintained to prevent electrolyte imbalance)

Step 3 - Fluid Restriction

Since Na+ is 116 mmol/L (well below 125 mmol/L), fluid restriction is mandatory - limit to 1,000-1,500 mL/day
Harrison's Principles 22E states: "Fluid intake may be restricted in patients with hyponatraemia (serum sodium <125 mEq/L)"

Step 4 - Large-Volume Paracentesis (LVP) if Grade 3 Ascites

If ascites is tense/refractory, therapeutic paracentesis (4-6 litres) should be performed
MUST give albumin infusion (8 g per litre of ascites drained) to prevent post-paracentesis circulatory dysfunction (PPCD) and hepatorenal syndrome - critically important in a patient with albumin already at 23 g/L
Sleisenger & Fordtran's recommends albumin infusion with each LVP

Step 5 - Diagnostic Paracentesis (IMMEDIATE PRIORITY)

Perform diagnostic tap to rule out Spontaneous Bacterial Peritonitis (SBP) - a life-threatening complication
Send ascitic fluid for: neutrophil count (SBP if >250 cells/mm³), culture, albumin, protein
If SBP confirmed: start empiric IV cefotaxime 2g TDS + albumin 1.5 g/kg on day 1 and 1 g/kg on day 3

Drugs to AVOID in ascites:

NSAIDs (reduce renal prostaglandins → AKI)
ACE inhibitors / ARBs (cause renal hypoperfusion)
Nephrotoxic drugs

2. Management of CONFUSION (Hepatic Encephalopathy)

The confusion in this patient is overt hepatic encephalopathy (OHE) - caused by ammonia accumulation from impaired hepatic metabolism.

Immediate Steps:

Identify and treat precipitating factors:
- GI bleed (check urea - his is slightly high, consider upper GI endoscopy)
- Infection/SBP (diagnostic paracentesis as above)
- Drugs - TEMAZEPAM 10 mg nightly is a MAJOR concern (see below)
- Dehydration/electrolyte imbalance (hyponatraemia already present)
- Constipation (already on lactulose - good)
Stop Temazepam IMMEDIATELY
- Benzodiazepines are metabolized in the liver and accumulate in hepatic impairment
- They directly precipitate and worsen hepatic encephalopathy by enhancing GABA-ergic neurotransmission (same neurotransmitter system implicated in HE)
- Yamada's Textbook of Gastroenterology states: "sedative medications, opioids, and other psychoactive medications must be stopped if possible" in HE management
- This is likely a direct drug-induced trigger of his confusion
Lactulose (already prescribed - continue and optimize)
- Mechanism: reduces gut pH → converts NH₃ (absorbable) to NH₄⁺ (non-absorbable) → less ammonia enters portal circulation; also acts as osmotic laxative to flush ammonia-producing bacteria
- The current dose is lactulose 10 ml BD - this may need titration upward to achieve 2-3 soft stools per day (the therapeutic target)
- In severe HE: give 30-45 ml every 1-2 hours until bowels open, then reduce to maintenance
- Can also be given as enema (300 mL in 700 mL water) if patient cannot swallow safely
Rifaximin (add if available/HE recurs)
- Non-absorbable antibiotic that reduces ammonia-producing gut bacteria
- 550 mg twice daily - highly effective for secondary prophylaxis of HE
- Not typically first-line for acute episode but should be considered given severity
Nutritional support
- Do NOT restrict protein (old practice was wrong)
- Give 35-40 kcal/kg/day and 1.2-1.5 g protein/kg/day
- Prefer plant-based/branched-chain amino acid (BCAA)-enriched protein
- Correct zinc deficiency if present (common in alcoholic liver disease)
Airway protection
- Assess GCS - if severe encephalopathy (Grade 3-4), may need ICU admission and airway protection/intubation

3. Management of NAUSEA and VOMITING

Nausea/vomiting here is multifactorial:

Hepatic encephalopathy
Severe hyponatraemia (Na+ 116)
Underlying liver failure
Possible GI bleed

Treatment:

Correct hyponatraemia carefully - slow correction (max 6-8 mmol/L/day) with fluid restriction. Rapid correction risks osmotic demyelination syndrome
Antiemetic therapy:
- Metoclopramide or ondansetron - safer options
- Avoid prochlorperazine and haloperidol in severe liver disease (hepatotoxic potential, reduce seizure threshold)
- Avoid domperidone (prolongs QT, risk in liver disease)
Maintain IV access - if patient cannot take oral medications due to vomiting, medications including lactulose may need to be given via nasogastric tube or IV alternatives

Summary of Initial Treatment Plan

Problem	Treatment
Ascites	Sodium restriction, spironolactone dose review, add furosemide if needed, LVP + albumin if tense, fluid restrict to 1-1.5 L/day
Hyponatraemia (Na 116)	Fluid restriction 1-1.5 L/day, cautious slow correction
Hepatic Encephalopathy	STOP temazepam, optimize lactulose to 2-3 stools/day, consider rifaximin, treat SBP/GI bleed if present
Nausea/Vomiting	Correct electrolytes, ondansetron/metoclopramide, NGT if unable to swallow
Coagulopathy (PT 135 sec)	Vitamin K IV 10 mg, FFP if active bleeding, avoid invasive procedures where possible
Jaundice/liver failure	Stop alcohol (counselling), nutritional support, monitor for HRS

Critical drug review: Temazepam must be stopped - it is the most likely pharmacological precipitant of this patient's encephalopathy and is dangerous in hepatic impairment. Spironolactone dose should be reviewed given severe hyponatraemia. - Yamada's Textbook of Gastroenterology; Sleisenger & Fordtran's GI and Liver Disease

This is a shared conversation. Sign in to Orris to start your own chat.